[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 27, 2013

Antiviral Therapy and Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence

Author Affiliations

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

Author Affiliation: Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch, Taipei, Taiwan (hsu.chingsheng@gmail.com).

JAMA. 2013;309(8):765. doi:10.1001/jama.2013.568

To the Editor: Although using antiviral therapy to suppress hepatitis B virus (HBV) replication after curative resection of hepatocellular carcinoma (HCC) is thought to potentially reduce the rate of HCC recurrence, studies regarding the efficacy of nucleoside analogues in this clinical setting are limited and thus controversial.1 In the study by Dr Wu and colleagues,2 the authors used the Taiwan National Health Insurance Research Database for analysis and reported that the use of a nucleoside analogue was associated with a lower risk of HCC recurrence among patients with HBV-related HCC after liver resection.